Modality
Bispecific Ab
MOA
SGLT2i
Target
FXIa
Pathway
STING
MGMDD
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
Apr 2017
→ Mar 2027
Phase 1Current
NCT06915613
1,213 pts·MG
2024-02→2027-03·Active
NCT03675787
837 pts·MDD
2017-04→2027-01·Completed
2,050 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-01-2810mo awayInterim· MDD
2027-03-0911mo awayInterim· MG
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Complet…
P1
Active
Catalysts
Interim
2027-01-28 · 10mo away
MDD
Interim
2027-03-09 · 11mo away
MG
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |